is tirzepatide a glp-1 receptor agonist How Does Work? PDB-101: Molecule of the Month:

In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide

Diabetes mellitus is a major risk factor for both cardiovascular and chronic kidney disease (CKD) while CKD is also associated with cardiovascular morbidity

GLP-1/GIP Therapy Discontinuation: Why the How Matters One of the most-discussed challenges with GLP-1/GIP agonists such as tirzepatide (Mounjaro) is weight regain after stopping therapy

These medicines work best when used as ongoing treatment, similar to medicine for high blood pressure or diabetes

At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide

This probiotic formulation includes strains that promote gut health and improve digestion